How can people get equal access to pharmaceuticals, Dr. Nina Lathia?

Klicken Sie auf den unteren Button, um den Inhalt von zu laden.

Inhalt laden

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, socio-economic status or any other individual factors, wrote Dr. Utibe R. Essien in an Jama article 2021. But how does reality look like? Equality in access starts with the generalizability of RCT data and the inclusion and exclusion criteria for these studies. But it does not stop there. How do regulators, payers and physicians work against inequality? The market access veteran Dr. Stefan Walzer and the Canadian health economist Dr. Nina Lathia have discussed these pharmacoequity issues from a global perspective. What does this mean for drug development? What does this mean for clinical trials?

Let’s not leave these questions with politicians alone. The voice from all stakeholders is needed and wanted. 


Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit:


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #Canada #pharmacoequity #pharma #healthcare